EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR ‐Mutated Advanced Nonsmall‐Cell Lung Cancer

Chia-Yu Kuo iD, Tien-Chi Huang, Chih-Jen Yang iD, Mei-Hsuan Lee, Jui-Ying Lee, Ying-Ming Tsai, Kuan-Li Wu, Cheng-Hao Chuang iD, Inn-Wen Chong, Jen-Yu Hung

The Kaohsiung Journal of Medical Sciences · 2025

DOI: 10.1002/kjm2.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2025. Verfasst von Chia-Yu Kuo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical Universit…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are indicated for advanced lung adenocarcinoma patients harboring susceptible EGFR mutations. The aim of this retrospective study was to compare the effectiveness of different generations of EGFR TKIs. We enrolled 421 patients with stage IV lung adenocarcinoma and sensitizing EGFR mutations receiving an EGFR‐TKI as their first‐line therapy, including first‐generation (1st G, gefitinib and erlotinib), second‐generation (2nd G, afatinib), and third‐generation (3rd G, osimertinib) EGFR TKIs. The median progression free survival (PFS) (12.10 vs. 16.67 months vs. not reached; p = 0.0002) and overall survival (OS) (31.23 vs. 45.97 months vs. not reached; p = 0.0215) were significantly different between different generations of EGFR TKIs. 3rd G EGFR TKI provided the best PFS, particularly in patients with exon 19 deletion. The patients receiving 1st G EGFR TKIs ( p = 0.005), with exon 19 deletion ( p = 0.001) and PFS ≥ 270 days ( p = 0.012) had a significantly higher T790M mutation rate. There was no survival difference between the patients receiving frontline 3rd G EGFR TKI and those receiving 3rd G EGFR TKI as sequential therapy (median OS 46.60 months vs. not reached, p = 0.1941). The OS of the patients who did not receive 3rd G EGFR TKI as sequential therapy was significantly worse than those receiving 3rd G EGFR TKI as first‐line therapy (median OS 22.47 months vs. not reached, p = 0.0042). In conclusion, 3rd G EGFR TKI may provide better survival benefits as first‐line therapy for patients harboring sensitizing EGFR mutations, particularly those with exon 19 deletion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutationHumansErbB ReceptorsMaleFemaleAgedMiddle AgedRetrospective StudiesGefitinibErlotinib HydrochlorideAdultAged, 80 and overAfatinibTreatment OutcomeAcrylamidesProgression-Free SurvivalAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

epidermal growth factor receptorlung cancertyrosine kinase inhibitor

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanGefitinibErlotinib HydrochlorideAfatinibosimertinibAcrylamidesAniline CompoundsIndoles

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan.
  • School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Division of Chest Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Chia-Yu Kuo, Chih-Jen Yang, Cheng-Hao Chuang

Zitieren

APA

Kuo, C. Y., Huang, T. C., Yang, C. J., Lee, M. H., Lee, J. Y., Tsai, Y. M., Wu, K. L., Chuang, C. H., Chong, I. W., & Hung, J. Y. (2025). Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR ‐Mutated Advanced Nonsmall‐Cell Lung Cancer. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.70105

Vancouver

Kuo CY, Huang TC, Yang CJ, Lee MH, Lee JY, Tsai YM, et al. Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR ‐Mutated Advanced Nonsmall‐Cell Lung Cancer. The Kaohsiung Journal of Medical Sciences. 2025. doi:10.1002/kjm2.70105

BibTeX
@article{Kuo2025,
  author = {Kuo, Chia-Yu and Huang, Tien-Chi and Yang, Chih-Jen and Lee, Mei-Hsuan and Lee, Jui-Ying and Tsai, Ying-Ming and Wu, Kuan-Li and Chuang, Cheng-Hao and Chong, Inn-Wen and Hung, Jen-Yu},
  title = {Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR ‐Mutated Advanced Nonsmall‐Cell Lung Cancer},
  journal = {The Kaohsiung Journal of Medical Sciences},
  year = {2025},
  doi = {10.1002/kjm2.70105}
}
Kostenlos starten →